Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Loading live signals…
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Dyne Therapeutics announces a proposed public offering of common stock to raise $300 million. The offering will have Morgan Stanley, Jefferies, and Evercore ISI as joint book-running managers.
PUBLIC · DYNJul 21, 2026•6 days ago
Amount Raised
$300 Million
Round Type
Post-IPO Equity
WalthamBiotechnologyHealth CareTherapeuticsInvestors
Raymond JamesLife Sci CapitalEvercore IsiJefferiesMorgan Stanley
Description
Dyne Therapeutics, Inc. has commenced an underwritten public offering of $300,000,000 of shares of its common stock. This offering is subject to market and other conditions. Dyne intends to grant underwriters a 30-day option for an additional $45,000,000
Related People
Suggested for you
1 contactFunding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech
Watching Dyne Therapeutics? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your plan